共 50 条
- [21] Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trialBRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (04) : 575 - 578Furtado, MichelleDyer, Martin J. S.Johnson, RodBerrow, MargieRule, Simon
- [22] UPDATED RESULTS OF A PHASE II TRIAL OF BENDAMUSTINE IN RELAPSED AND REFRACTORY HODGKIN LYMPHOMAANNALS OF ONCOLOGY, 2011, 22 : 180 - 181Moskowitz, A. J.Hamlin, P.Gerecitano, J.Horwitz, S.Matasar, M.Noy, A.Palomba, M. L.Portlock, C.Straus, D.Graustein, T.Zelenetz, A.Moskowitz, C.
- [23] Results of a phase I/II multicenter trial of galiximab (IDEC-114, anti-CD80 antibody) therapy for relapsed or refractory follicular lymphoma.BLOOD, 2003, 102 (11) : 647A - 648ACzuczman, MWitzig, TEVose, JMYounes, AEmmanouilides, CMiller, TPMoore, JOLeonard, JPGordon, LFinucane, DWhiteley, MLeigh, BR
- [24] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple MyelomaBLOOD, 2012, 120 (21)Lendvai, NikolettaLandau, HeatherLesokhin, AlexanderTsakos, IoannaKoehne, GuentherChung, DavidDevlin, SeanHassoun, HaniGiralt, Sergio A.
- [25] Phase II Trial of Clofarabine With Topotecan, Vinorelbine, and Thiotepa in Pediatric Patients With Relapsed or Refractory Acute LeukemiaPEDIATRIC BLOOD & CANCER, 2014, 61 (03) : 431 - 435Shukla, NeeravKobos, RachelRenaud, ThomasSteinherz, Laurel J.Steinherz, Peter G.
- [26] Copanlisib in patients with relapsed or refractory follicular lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Dreyling, Martin H.Santoro, ArmandoLeppa, SirpaDemeter, JuditFollows, GeorgeLenz, GeorgKim, Won SeogMollica, LuiginaNagler, ArnonDiong, Colin PhippsProvencio, MarianoStevens, Don A.Trevarthen, DavidMagagnoli, MassimoCupit, LisaYin, ShuxinHiemeyer, Florian-Vargas, Jose E. GarciaChilds, Barrett H.Zinzani, Pier Luigi
- [27] Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.BLOOD, 2008, 112 (11) : 765 - 766Arai, SallyLetsinger, ReneeJohnston, LauraLaport, GinnaLowsky, RobertMiklos, DavidShizuru, JudithWeng, Wen-KaiWong, RubyLavori, PhilipBlume, KarlNegrin, RobertHorning, Sandra
- [28] A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology non-Hodgkin's lymphoma.BLOOD, 2003, 102 (11) : 288B - 288BPiliotis, EGMangel, JBuckstein, RImrie, KSpaner, DReis, MFoden, CBoudreau, ARichardson, PRichardson, JBerinstein, N
- [29] Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaJOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28) : 3109 - +Moskowitz, Alison J.Shah, GunjanSchoeder, HeikoGanesan, NivethaDrill, EstherHancock, HelenDavey, TheresaPerez, LeslieRyu, SunyoungSohail, SamiaSantarosa, AlaynaGalasso, NatashaNeuman, RachelLiotta, BrielleBlouin, WilliamKumar, AnitaLahoud, OscarBatlevi, Connie L.Hamlin, PaulStraus, David J.Rodriguez-Rivera, IldefonsoOwens, ColetteCaron, PhilipIntlekofer, Andrew M.Hamilton, AudreyHorwitz, Steven M.Falchi, LorenzoJoffe, ErelJohnson, WilliamLee, ChristinaPalomba, M. LiaNoy, ArielaMatasar, Matthew J.Pongas, GeorgiosSalles, GillesVardhana, SantoshaSanin, Beatriz Willsvon Keudell, GottfriedYahalom, JoachimDogan, AhmetZelenetz, Andrew D.Moskowitz, Craig H.
- [30] A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Kim, Won SeogYoon, Dok HyunSong, YuqinYang, HaiyanCao, JunningJi, DongmeiKoh, YoungilJing, HongmeiEom, Hyeon SeokKwak, Jae-YongLee, Won-SikLee, Jong SeokShin, Ho-JinJin, JieWang, MeiLi, JingrunHuang, XubinDeng, XueyuanYang, ZhenfanZhu, Jun